-transparent.png){kind=logo}
In eight patients with extrinsic bronchial asthma the effect of inhaled verapamil (3 and 6 mg) was compared with saline on bronchial challenge with extracts of Dermatophagoides pteronyssinus. There was no significant difference in the baseline FEV1 before and after inhalation of saline or verapamil 2.5 mg/ml. However, verapamil at a higher concentration (5 mg/ml) caused bronchoconstriction in four patients who had to be excluded from the part of the study. Verapamil at both these concentrations failed to have an effect on the allergen-induced bronchoconstriction. These findings suggest that verapamil given by inhalation does not prevent mediator release from the lung mast cells following specific allergen challenge.
K R Patel, and
M R Al Shama, and
J W Kerr
April 1983,
The Journal of allergy and clinical immunology,
K R Patel, and
M R Al Shama, and
J W Kerr
July 1991,
Chest,
K R Patel, and
M R Al Shama, and
J W Kerr
June 1993,
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,
K R Patel, and
M R Al Shama, and
J W Kerr
August 1985,
Chest,
K R Patel, and
M R Al Shama, and
J W Kerr
January 1986,
Allergologia et immunopathologia,
K R Patel, and
M R Al Shama, and
J W Kerr
September 1981,
Clinical allergy,
K R Patel, and
M R Al Shama, and
J W Kerr
October 1985,
The Journal of allergy and clinical immunology,
K R Patel, and
M R Al Shama, and
J W Kerr
January 1996,
American journal of respiratory and critical care medicine,
K R Patel, and
M R Al Shama, and
J W Kerr
May 1989,
British journal of clinical pharmacology,
K R Patel, and
M R Al Shama, and
J W Kerr
November 1988,
Arerugi = [Allergy],
